Nomura Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $59.7M | Sell |
120,235
-932
| -0.8% | -$413K | 0.13% | 157 |
|
|
2026
Q1 | $54.1M | Buy |
121,167
+1,469
| +1% | +$685K | 0.14% | 150 |
|
|
2025
Q4 | $54.3M | Buy |
119,698
+7,365
| +7% | +$3.17M | 0.14% | 157 |
|
|
2025
Q3 | $44M | Sell |
112,333
-46,583
| -29% | -$19.5M | 0.11% | 189 |
|
|
2025
Q2 | $70.7M | Buy |
158,916
+5,621
| +4% | +$2.59M | 0.19% | 112 |
|
|
2025
Q1 | $74.3M | Buy |
153,295
+3,496
| +2% | +$1.63M | 0.23% | 100 |
|
|
2024
Q4 | $60.3M | Sell |
149,799
-5,095
| -3% | -$2.36M | 0.18% | 119 |
|
|
2024
Q3 | $72M | Buy |
154,894
+6,831
| +5% | +$3.28M | 0.22% | 100 |
|
|
2024
Q2 | $69.4M | Buy |
148,063
+16,701
| +13% | +$7.25M | 0.24% | 87 |
|
|
2024
Q1 | $54.9M | Sell |
131,362
-19,353
| -13% | -$8.18M | 0.2% | 115 |
|
|
2023
Q4 | $61.3M | Sell |
150,715
-18,822
| -11% | -$6.95M | 0.25% | 90 |
|
|
2023
Q3 | $59M | Buy |
169,537
+3,852
| +2% | +$1.35M | 0.28% | 77 |
|
|
2023
Q2 | $58.3M | Sell |
165,685
-19,008
| -10% | -$6.4M | 0.27% | 87 |
|
|
2023
Q1 | $58.2M | Sell |
184,693
-111,826
| -38% | -$33.5M | 0.31% | 76 |
|
|
2022
Q4 | $85.6M | Sell |
296,519
-22,660
| -7% | -$6.91M | 0.5% | 40 |
|
|
2022
Q3 | $92.4M | Buy |
319,179
+6,227
| +2% | +$1.79M | 0.59% | 32 |
|
|
2022
Q2 | $88.2M | Sell |
312,952
-2,052
| -0.7% | -$549K | 0.55% | 37 |
|
|
2022
Q1 | $82.2M | Buy |
315,004
+18,150
| +6% | +$4.31M | 0.45% | 43 |
|
|
2021
Q4 | $65.2M | Buy |
296,854
+56,197
| +23% | +$10.9M | 0.33% | 70 |
|
|
2021
Q3 | $43.7M | Buy |
240,657
+12,681
| +6% | +$2.48M | 0.25% | 100 |
|
|
2021
Q2 | $46M | Sell |
227,976
-11,180
| -5% | -$2.34M | 0.27% | 89 |
|
|
2021
Q1 | $51.4M | Sell |
239,156
-11,802
| -5% | -$2.59M | 0.33% | 73 |
|
|
2020
Q4 | $59.3M | Buy |
250,958
+10,907
| +5% | +$2.5M | 0.4% | 60 |
|
|
2020
Q3 | $65.3M | Buy |
240,051
+57,031
| +31% | +$15.7M | 0.5% | 43 |
|
|
2020
Q2 | $53.1M | Buy |
183,020
+12,100
| +7% | +$3.28M | 0.45% | 52 |
|
|
2020
Q1 | $40.7M | Buy |
170,920
+113,007
| +195% | +$25.9M | 0.42% | 57 |
|
|
2019
Q4 | $12.7M | Sell |
57,913
-3,556
| -6% | -$720K | 0.11% | 185 |
|
|
2019
Q3 | $10.4M | Buy |
61,469
+3,536
| +6% | +$626K | 0.1% | 213 |
|
|
2019
Q2 | $10.6M | Sell |
57,933
-352
| -0.6% | -$61.5K | 0.11% | 192 |
|
|
2019
Q1 | $10.7M | Sell |
58,285
-1,358
| -2% | -$251K | 0.11% | 183 |
|
|
2018
Q4 | $9.88M | Buy |
59,643
+3,539
| +6% | +$613K | 0.11% | 183 |
|
|
2018
Q3 | $10.8M | Buy |
56,104
+716
| +1% | +$127K | 0.1% | 170 |
|
|
2018
Q2 | $9.41M | Sell |
55,388
-1,428
| -3% | -$221K | 0.1% | 187 |
|
|
2018
Q1 | $9.26M | Buy |
56,816
+1,193
| +2% | +$195K | 0.1% | 174 |
|
|
2017
Q4 | $8.34M | Buy |
55,623
+23,823
| +75% | +$3.53M | 0.1% | 188 |
|
|
2017
Q3 | $4.83M | Sell |
31,800
-21,390
| -40% | -$3.22M | 0.06% | 273 |
|
|
2017
Q2 | $6.86M | Buy |
53,190
+1,474
| +3% | +$177K | 0.09% | 212 |
|
|
2017
Q1 | $5.66M | Buy |
51,716
+14,699
| +40% | +$1.29M | 0.08% | 251 |
|
|
2016
Q4 | $2.73M | Sell |
37,017
-15,579
| -30% | -$1.27M | 0.05% | 348 |
|
|
2016
Q3 | $4.59M | Buy |
52,596
+860
| +2% | +$81.3K | 0.08% | 254 |
|
|
2016
Q2 | $4.45M | Buy |
51,736
+15,281
| +42% | +$1.32M | 0.08% | 241 |
|
|
2016
Q1 | $2.9M | Buy |
36,455
+7,783
| +27% | +$704K | 0.06% | 317 |
|
|
2015
Q4 | $3.61M | Sell |
28,672
-6,063
| -17% | -$732K | 0.07% | 266 |
|
|
2015
Q3 | $3.62M | Buy |
34,735
+1,365
| +4% | +$175K | 0.07% | 262 |
|
|
2015
Q2 | $4.12M | Sell |
33,370
-3,875
| -10% | -$488K | 0.08% | 251 |
|
|
2015
Q1 | $4.39M | Buy |
37,245
+3,455
| +10% | +$414K | 0.08% | 238 |
|
|
2014
Q4 | $4.03M | Buy |
33,790
+6,949
| +26% | +$783K | 0.07% | 259 |
|
|
2014
Q3 | $3.02M | Buy |
26,841
+1,678
| +7% | +$160K | 0.05% | 299 |
|
|
2014
Q2 | $2.38M | Buy |
25,163
+145
| +0.6% | +$10.2K | 0.04% | 342 |
|
|
2014
Q1 | $1.77M | Sell |
25,018
-9,130
| -27% | -$723K | 0.03% | 406 |
|
|
2013
Q4 | $2.54M | Buy |
34,148
+8,410
| +33% | +$586K | 0.05% | 333 |
|
|
2013
Q3 | $1.95M | Sell |
25,738
-7,432
| -22% | -$591K | 0.04% | 379 |
|
|
2013
Q2 | $2.65M | Buy |
+33,170
| New | +$2.44M | 0.05% | 348 |
|
Other funds holding VRTX
Nomura Asset Management's VRTX Position: Q2 2026 in Review
Nomura Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.77% in Q2 2026, selling an estimated $413K and leaving 120,235 shares worth $59.7M. The position accounts for 0.13% of the portfolio, ranked #157.
Nomura Asset Management first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $92.4M in Q3 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Nomura Asset Management held 120,235 shares of Vertex Pharmaceuticals worth $59.7M as of Q2 2026.
- Nomura Asset Management sold 932 Vertex Pharmaceuticals shares in Q2 2026, an estimated $413K.
- Vertex Pharmaceuticals made up 0.13% of Nomura Asset Management's portfolio in Q2 2026, its #157 holding.
- Nomura Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Nomura Asset Management's Vertex Pharmaceuticals position peaked at $92.4M in Q3 2022.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.